质谱法与二代流式检测可测量残留病灶评估骨髓瘤治疗反应
在GEM2012MENOS65和GEM2014MAIN试验中,比较血清定量免疫沉淀质谱法(QIP-MS)与骨髓二代流式(NGF)检测可测量残留病灶(MRD)的性能,配对样本取自诱导后、移植后、巩固后及维持24周期后。各时间点两种方法均能区分无进展生存期显著不同的两组;维持或转为MRD阴性者生存更长,QIP-MS再现MRD与 imminent 临床进展高风险相关。
要点
- 各时间点NGF与QIP-MS均能区分无进展生存期显著不同的两组患者
- 维持或转为MRD阴性者生存长于持续或转为MRD阳性者
- QIP-MS再现MRD与即将临床进展的高风险相关
核心结论
- NGF与MS的MRD评估在单时间点和动力学上具有相似的预后价值。
研究设计与样本
- 在GEM2012MENOS65和GEM2014MAIN试验中,比较血清QIP-MS与骨髓NGF检测配对样本的MRD性能,样本取自诱导后、移植后、巩固后及维持24周期后。
主要发现
- 各时间点NGF和QIP-MS均能将患者分为无进展生存期显著不同的两组。
- 维持或转为MRD阴性者生存更长,显著优于持续或转为MRD阳性者。
- QIP-MS再现MRD与即将临床进展的高风险相关。
临床怎么用
- MS的微创性使MRD监测成为MM高灵敏度反应评估的突破。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Quantitative immunoprecipitation mass spectrometry (QIP-MS) allows the identification of the M-protein in patients with multiple myeloma (MM) otherwise in complete response, and could be considered suitable for measurable residual disease (MRD) evaluation in peripheral blood. In the context of the GEM2012MENOS65 and GEM2014MAIN trials, we compared the performance of QIP-MS in serum with next-generation flow (NGF) cytometry in bone marrow to assess MRD in paired samples obtained postinduction, transplant, consolidation and after 24 cycles of maintenance. At each time point, both NGF and QIP-MS were able to segregate 2 groups of patients with significantly different progression-free survival; when the evolution of the results obtained with either method was considered, maintaining or converting to MRD negativity was associated with longer survival, significantly better when compared with sustaining or converting to MRD positivity. Reemergence of MRD by QIP-MS was associated with high risk of imminent clinical progression. In conclusion, MRD evaluation by NGF and MS achieves similar prognostic value based in single time point assessments and kinetics. Thus, the minimally invasive nature of MRD monitoring by MS represents a breakthrough in highly sensitive response assessment in MM. The trials were registered at www.clinicaltrials.gov as #NCT01916252 (GEM2012MENOS65) and at EudraCT as #2012-005683-10; and as #NCT02406144 (GEM2014MAIN) and at EudraCT as 2014-00055410.
引用
- Puig N, Agulló C, Contreras T, et al. Measurable residual disease by mass spectrometry and next-generation flow to assess treatment response in myeloma. Blood. 2024. PMID: 39293025. doi:10.1182/blood.2024024995
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。